PENBRITIN ORAL SUSPENSION AMPICILLIN

Description

PENBRITIN® is indicated for the treatment of infections by Gram positive and negative cocci and susceptible bacilli that cause infections of various locations and severities, acute, chronic and recurrent, including: Group B Streptococcus, Enterococcus faecalis and faecium, Haemophilus influenzae , Listeria monocytogenes, Proteus mirabilis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus sp, Neisseria sp, Branhamella catarrhalis, Klebsiella pneumoniae.

Tract infections:

Respiratory.

Digestive.

Urinary.

Genital.

Meningitis and septicemia.

Endocarditis.

Treatment and prophylaxis in dentistry.

Respiratory:

Acute otitis media.

Croup.

Laryngotracheobronchitis.

Sinusitis.

Nasopharyngoconjunctivitis.

Pneumonia.

Bronchopneumonia.

Digestive:

Shigellosis.

Salmonellosis.

Stomach flu.

Urinary:

Pyelonephritis

Cystitis.

Urethritis

Genitalia and OB / GYN:

During pregnancy.

In premature rupture of chorionic membranes.

Puerperal and neonatal infections by Listeria monocytogenes.

Eye infections

Skin and osteoarticular tissue.

In infection by strains of intermediate sensitivity, PENBRITIN® associated with an aminoglycoside increases its effectiveness. In all cases, before treatment with PENBRITIN®, bacteriological cultures should be requested to identify the causative germs and their sensitivity to antibiotics.